Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming von Valmori, Danila, Souleimanian, Naira E, Tosello, Valeria, Bhardwaj, Nina, Adams, Sylvia, O'Neill, David, Pavlick, Anna, Escalon, Juliet B, Cruz, Crystal M, Angiulli, Angelica, Angiulli, Francesca, Mears, Gregory, Vogel, Susan M, Pan, Linda, Jungbluth, Achim A, Hoffmann, Eric W, Venhaus, Ralph, Ritter, Gerd, Old, Lloyd J, Ayyoub, Maha

Volltext

Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series von M. Hughes, PharmD, BCOP, David, Toste, DNP, APN, Charina, Nelson, ACNP-BC, Christopher, Escalon, ANP, Juliet, Blevins, PA-C, Frances, Shah, RPh, BCOP, Bhavesh

Volltext

Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations von Richard, Shambavi, Lancman, Guido, Thibaud, Santiago, Chari, Ajai, Parekh, Samir, Rossi, Adriana, Cho, Hearn J., Sanchez, Larysa, Richter, Joshua, Rodriguez, Cesar, Aronson, Elizabeth, Louw, Karen, Purcell, Kiah, Verina, Daniel, Escalon, Juliet, Jagannath, Sundar

Volltext

Extramedullary Relapse Post CAR-T von Richard, Shambavi, Lancman, Guido, Rossi, Adriana, Chari, Ajai, Parekh, Samir, Sanchez, Larysa, Rodriguez, Cesar, Cho, Hearn J., Richter, Joshua, Thibaud, Santiago, Purcell, Kiah, Aronson, Elizabeth, Verina, Daniel, Escalon, Juliet, Louw, Karen, Jagannath, Sundar

Volltext

Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Rel... von Mancia, Stefania Stefania, Farrell, Annamaria, Louw, Karen, Florendo, Erika, Aronson, Elizabeth, Purcell, Kiah, Catamero, Donna D, Escalon, Juliet, Thomas, Joanne, Aponte, Annel, Lamb, Angela, Kirke, Diana, Lucas, Aimee, Jagannath, Sundar, Cho, Hearn Jay, Parekh, Samir, Richter, Joshua, Sanchez, Larysa, Chari, Ajai

Volltext

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma von Sabado, Rachel Lubong, Pavlick, Anna, Gnjatic, Sacha, Cruz, Crystal M, Vengco, Isabelita, Hasan, Farah, Spadaccia, Meredith, Darvishian, Farbod, Chiriboga, Luis, Holman, Rose Marie, Escalon, Juliet, Muren, Caroline, Escano, Crystal, Yepes, Ethel, Sharpe, Dunbar, Vasilakos, John P, Rolnitzsky, Linda, Goldberg, Judith, Mandeli, John, Adams, Sylvia, Jungbluth, Achim, Pan, Linda, Venhaus, Ralph, Ott, Patrick A, Bhardwaj, Nina

Volltext

A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma von Chari, Ajai, Cho, Hearn Jay, Parekh, Samir, Lau, Kenneth, Morgan, Gillian, Catamero, Donna, Cortes, Melissa, Curtis, Meredith, Escalon, Juliet, Florendo, Erika, Verina, Daniel, Stevens, Nadege, Chan, Elaine, Garcia, Katarzyna, La, Lisa, Shields, Marisa, Strumolo, Gina, Jagannath, Sundar

Volltext

Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib von Chari, Ajai, Cho, Hearn Jay, Parekh, Samir, Osman, Keren, Goldstein, Talia, Morgan, Gillian, La, Lisa, Carter, Crystle, Catamero, Donna, Escalon, Juliet, Verina, Daniel, Florendo, Erika, Yum, Moon-hee, Stevens, Nadege, Gullie, Jude, Chan, Elaine, Jagannath, Sundar

Volltext

A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma von Chari, Ajai, Cho, Hearn J., Parekh, Samir S., Dhadwal, Amishi, Garcia, Katarzyna, Morgan, Gillian, Belostotsky, Natalie, Carter, Crystle, Catamero, Donna, Escalon, Juliet, Verina, Daniel, Yum, Moon-Hee, La, Lisa, Chan, Elaine, Gullie, Jude, Jagannath, Sundar

Volltext

Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab von Chari, Ajai, Satta, Toshihisa, Tayal, Amit, Jagannath, Sundar, Cho, Hearn Jay, Parekh, Samir, Lau, Kenneth, Morgan, Gillian, Catamero, Donna, Escalon, Juliet, Florendo, Erika, Verina, Daniel, Doshi, Parul, Feng, Huaibao, Uhlar, Clarissa, Khan, Imran, Ahmadi, Tahamtan, Voorhees, Peter M., Mateos, Maria-Victoria, Arinsburg, Suzanne

Volltext

A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma von Chari, Ajai, Cho, Hearn Jay, Leng, Siyang, Dhadwal, Amishi, Morgan, Gillian, La, Lisa, Garcia, Katarzyna, Carter, Crystle, Catamero, Donna, Escalon, Juliet, Florendo, Erika, Stevens, Nadege, Verina, Daniel, Yum, Moon-hee, Gullie, Jude, Chan, Elaine, Jagannath, Sundar, Leshchenko, Violetta V, Lagana, Alessandro, Qi, Jingjing, Patel, Manishkumar, Seunghee, Kim-Schulze, Parekh, Samir

Volltext

Phase I/II trial of intraperitoneal implantation of agarose-agarose macrobeads (MB) containing mouse renal adenocarcinoma cells (RENCA) in patients (pts) with advanced colorectal c... von Ocean, Allyson J., Parikh, Tapan, Berman, Nathaniel, Escalon, Juliet, Shah, Manish A., Andrada, Zoe, Akahoho, Eugene, Pogoda, Janice M., Stoms, George B., Escobia, Verula B, Ruggiero, Joseph T., Fahey, Thomas J., Smith, Barry H.

Volltext

Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma von Sabado, Rachel Lubong, Pavlick, Anna C., Gnjatic, Sacha, Cruz, Crystal M, Vengco, Isabelita, Hasan, Farah, Darvishian, Farbod, Chiriboga, Luis, Holman, Rose Marie, Escalon, Juliet, Muren, Caroline, Escano, Crystal, Yepes, Ethel, Sharpe, Dunbar, Adams, Sylvia, Ott, Patrick Alexander, Jungbluth, Achim A, Pan, Linda S., Venhaus, Ralph Rudolph, Bhardwaj, Nina

Volltext

Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma von Sabado, Rachel Lubong, Pavlick, Anna C., Gnjatic, Sacha, Cruz, Crystal M, Vengco, Isabelita, Hasan, Farah, Darvishian, Farbod, Chiriboga, Luis, Holman, Rose Marie, Escalon, Juliet, Muren, Caroline, Escano, Crystal, Yepes, Ethel, Sharpe, Dunbar, Adams, Sylvia, Ott, Patrick Alexander, Jungbluth, Achim A, Pan, Linda S., Venhaus, Ralph Rudolph, Bhardwaj, Nina

Volltext

Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study von Hochster, Howard, Chen, Thomas T, Lu, Janice M, Hills, Day, Sorich, Joan, Escalon, Juliet, Ivy, Percy, Liebes, Leonard, Muggia, Franco

Volltext

Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma von Sabado, Rachel L, Pavlick, Anna, Gnjatic, Sacha, Cruz, Crystal, Vengco, Isabelita, Hasan, Farah, Darvishian, Farbod, Chiriboga, Luis, Holman, Rose Marie, Escalon, Juliet, Muren, Caroline, Escano, Crystal, Yepes, Ethel, Sharpe, Dunbar, Adams, Sylvia, Ott, Patrick, Jungbluth, Achim, Pan, Linda, Venhaus, Ralph, Bhardwaj, Nina

Volltext